RALPH R WEICHSELBAUM, M.D.
Radiology at Maryland Ave, Chicago, IL

6486170, Nov 26, 2002

May 24, 1994

08/248058

Dennis E. Hallahan - Des Plaines IL
Ralph R. Weichselbaum - Chicago IL
Donald W. Kufe - Wellesley MA

Arch Development Corporation - Chicago IL

A61K 3144

514297, 4352402, 4351731, 514747, 514263, 514291, 514169

A signaling pathway is identified that involves the activation of phospholipase A2 and protein kinase C in human cells, which in turn confers x-ray induction of the tumor necrosis factor (TNF) gene. Inhibition of phospholipase A2 abolishes radiation-mediated arachidonate production, as well as the subsequent activation of protein kinase C and TNF gene expression. These phospholipase A2 inhibitors may be used to ameliorate the adverse-effects of radiotherapy associated with TNF production.

7265356, Sep 4, 2007

Nov 29, 2004

10/998509

Charles A. Pelizzari - Chicago IL, US
Chin-Tu Chen - Lisle IL, US
Ralph R. Weichselbaum - Chicago IL, US
Samuel Hellman - Chicago IL, US

The University of Chicago - Chicago IL

G01T 1/24

25037009

In some embodiments, an image-guided radiotherapy apparatus and method is provided in which a radiotherapy radiation source and a gamma ray photon imaging device are positioned with respect to a patient area so that a patient can be treated by a beam emitted from the radiotherapy apparatus and can have images taken by the gamma ray photon imaging device. Radiotherapy treatment and imaging can be performed substantially simultaneously and/or can be performed without moving the patient in some embodiments. The gamma ray photon imaging device can be coupled and movable with respect to any part of a building structure, can be located on a portable frame movable to and from the radiotherapy radiation source and patient, or can take other forms. In some embodiments, the gamma ray photon imaging device can be used for imaging in connection with other types of medical interventions.

2005014, Jul 7, 2005

Sep 21, 2004

10/946365

Dennis Hallahan - Park Ridge IL, US
Ralph Weichselbaum - Chicago IL, US
Donald Kufe - Wellesley MA, US
Gregory Sibley - Chapel Hill NC, US
Bernard Roizman - Chicago IL, US

A61K048/00, C12N015/869

424093200, 435456000

The present invention is directed to novel methods of enhancing the effectiveness of DNA damaging agents by exposing cells to viruses prior to or during exposure to the damaging agent. In certain embodiments of the invention, the DNA damaging agent is ionizing radiation, the virus is an adenovirus, and the increase in cell killing is synergistic when compared to radiation alone.

2011005, Mar 3, 2011

Oct 13, 2010

12/903706

Donald KUFE - Wellesley MA, US
Ralph R. WEICHSELBAUM - Chicago IL, US

ARCH DEVELOPMENT CORPORATION - Chicago IL
DANA-FARBER CANCER INSTITUTE - Boston MA

C12N 13/00, C12N 5/00

4351731, 435375

The present invention relates to the signalling pathways connecting DNA damage, such as that induced by ionizing radiation or alkylating agents, and phosphorylation by tyrosine kinases.

6025365, Feb 15, 2000

Mar 25, 1997

8/826814

Ralph Weichselbaum - Chicago IL
Steven Chmura - Chicago IL
Jose Quintans - Chicago IL
Donald W. Kufe - Wellesley MA

Arch Development Corp. - Chicago IL
Dana-Farber Cancer Institute - Boston MA

A61N 4342, A61N 500

514298

Combination of low doses of irradiation and chelerythrine results in increased apoptosis in tumor cells. The doses of either irradiation or chelerythrine alone are such that increased apoptosis or decreased tumor growth or proliferation would not be expected.

7247297, Jul 24, 2007

Sep 16, 2002

10/244705

Ralph R. Weichselbaum - Chicago IL, US
Donald W. Kufe - Wellesley MA, US

The University of Chicago - Chicago IL
Dana-Farber Cancer Institute - Boston MA

A61K 48/00, A01N 63/00

424 932

The present invention provides for improved vectors for use in gene therapy. Utilizing the cancer specific DF3/MUC1 promoter to drive a replication essential gene, vectors are made conditionally replication-competent, permitting wider infection and expression of tumor cells. In addition, therapeutic genes and adjunct therapies further increase anti-tumor efficacy.

2011004, Feb 24, 2011

Oct 27, 2010

12/913459

Ralph R. Weichselbaum - Chicago IL, US
Zahra Shafaee - Bronxville NY, US
Wei Du - Chicago IL, US

The University of Chicago - Chicago IL

A61K 31/337, A61P 35/00, C12N 5/02

514449, 435375

The present invention relates to therapeutic combinations and methods of inhibiting the proliferation of cancerous cells, the abnormal growth of cells, and tumor cell growth using the combination of a hedgehog inhibitor with chemotherapy and/or radiation therapy. The present invention also relates to methods of enhancing the antiproliferative effect of chemotherapy and/or radiation therapy in a mammalian cancer patient undergoing either chemotherapy or radiation or a combination of radiation and chemotherapy by co-administering a therapeutically amount of a hedgehog inhibitor, concurrently or sequentially, with the chemotherapy and/or radiation therapy.

2005004, Mar 3, 2005

Oct 9, 2002

10/492239

Ralph Weichselbaum - Chicago IL, US
Bernard Roizman - Chicago IL, US
Nikolai Khodarev - Villa Park IL, US
Nalin Gupta - San Francisco CA, US

C12Q001/68, G01N033/53, G01N033/574

435006000, 435007230

This invention provides methods and kits for use in selecting approaches to treating cancer, as well as methods for identifying genes that can be used in such methods and kits.

8318691, Nov 27, 2012

Jun 7, 2010

12/802443

Ralph R. Weichselbaum - Chicago IL, US
Bernard Roizman - Chicago IL, US
Richard J. Whitley - Birmingham AL, US

Arch Development Corporation - Chicago IL
UAB Research Foundation - Birmingham AL

A61K 48/00

514 44A

Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.